$SBEV

Endovia Health Sciences, Inc.

0
1
0

No SEC Form 4 filings for $SBEV in the last 30 days.

See all $SBEV insider activity →
Low

Endovia Health Sciences, Inc. (EDVA): Unregistered Sales of Equity Securities

Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F

Endovia Health Sciences, Inc. (SBEV): Entry into a Material Definitive Agreement

Endovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich

SPLASH BEVERAGE GROUP, INC. (SBEV): Results of Operations and Financial Condition

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L

SBEV sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning SBEV (Endovia Health Sciences, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent SBEV coverage spans corporate actions, earnings and technology.

What's driving SBEV

  • Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F

    SEC EDGAR 8-K · Aug 28, 2026

  • Minor corporate action; limited immediate price impact.

    SEC EDGAR 8-K · Aug 26, 2026

  • First public disclosure of quarterly results; no specific financial figures provided.

    SEC EDGAR 8-K · Aug 20, 2026

  • The 8-K discloses a new collaboration framework where Lupvindol leads FDA regulatory work and Splash provides milestone funding and commercial support, which can change development timelines and funding needs.

    SEC EDGAR 8-K · Aug 4, 2026

  • The license expansion and planned veterinary JV are a near-term catalyst that can re-rate risk and valuation expectations for SBEV’s cannabinoid platform.

    benzinga.com · Jul 31, 2026

alphai scores every news story that mentions SBEV with an AI model for sentiment and relevance, and aggregates insider trades from Endovia Health Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SBEV

Score
$EDVALow

Endovia Health Sciences, Inc. (EDVA): Unregistered Sales of Equity Securities

Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F

$SBEVLow

Endovia Health Sciences, Inc. (SBEV): Entry into a Material Definitive Agreement

Endovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich

$SBEVLow

SPLASH BEVERAGE GROUP, INC. (SBEV): Results of Operations and Financial Condition

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences The Company’s loss from continuing operations declined by approximately 64% for the first six months of 2026 as cost reductions take hold FORT L

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On July 31, 2026, Splash Beverage Group, Inc. (the “Company”) entered into a Development and Collaboration Agreement (the “Collaboration Agreement”) with Lupvindol Biosciences Ltd. (“Lupvindol”), pursuant to which Lupvindol has

$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

$SBEVMed

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program Expansion broadens CannEpil into veterinary therapeutics as Splash advances its cannabinoid pharmaceutical development

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

$SBEVMed

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

$SBEVMed

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-10 2026-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor

Related tickers